+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Friedreich Ataxia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749283
  • Report
  • February 2019
  • Region: Global
  • 70 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Agios Pharmaceuticals Inc
  • Biovista Inc
  • Cardero Therapeutics Inc
  • Horizon Pharma Plc
  • Ixchel Pharma LLC
  • Panorama Research Inc
  • MORE
The global demand for Friedreich Ataxia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Friedreich Ataxia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Friedreich Ataxia pipeline companies from advancing their products into Phase 3 or Phase 4.

Friedreich Ataxia Report Description

The 2019 pipeline study on Friedreich Ataxia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Friedreich Ataxia pipeline compounds.

The Friedreich Ataxia pipeline guide presents information on all active drugs currently being developed for Friedreich Ataxia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Friedreich Ataxia pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Friedreich Ataxia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Friedreich Ataxia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Friedreich Ataxia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Friedreich Ataxia pipeline report includes
  • An overview of Friedreich Ataxia disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Friedreich Ataxia pipeline
  • Company wise list of Friedreich Ataxia pipeline
  • Mechanism of Action wise Friedreich Ataxia pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Friedreich Ataxia pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Friedreich Ataxia pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Friedreich Ataxia pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Agios Pharmaceuticals Inc
  • Biovista Inc
  • Cardero Therapeutics Inc
  • Horizon Pharma Plc
  • Ixchel Pharma LLC
  • Panorama Research Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Friedreich Ataxia Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Friedreich Ataxia Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Friedreich Ataxia pipeline, H1- 2019
3.5 Mechanism of Action wise Friedreich Ataxia Pipeline Candidates

4 Adverum Biotechnologies Inc Friedreich Ataxia Pipeline Details
4.1 Adverum Biotechnologies Inc Business Profile
4.2 Adverum Biotechnologies Inc Friedreich Ataxia Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Agios Pharmaceuticals Inc Friedreich Ataxia Pipeline Details
5.1 Agios Pharmaceuticals Inc Business Profile
5.2 Agios Pharmaceuticals Inc Friedreich Ataxia Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Amylyx Pharmaceutical Corp Friedreich Ataxia Pipeline Details
6.1 Amylyx Pharmaceutical Corp Business Profile
6.2 Amylyx Pharmaceutical Corp Friedreich Ataxia Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 BioElectron Technology Corp Friedreich Ataxia Pipeline Details
7.1 BioElectron Technology Corp Business Profile
7.2 BioElectron Technology Corp Friedreich Ataxia Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 BioMarin Pharmaceutical Inc Friedreich Ataxia Pipeline Details
8.1 BioMarin Pharmaceutical Inc Business Profile
8.2 BioMarin Pharmaceutical Inc Friedreich Ataxia Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Biovista Inc Friedreich Ataxia Pipeline Details
9.1 Biovista Inc Business Profile
9.2 Biovista Inc Friedreich Ataxia Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Cardero Therapeutics Inc Friedreich Ataxia Pipeline Details
10.1 Cardero Therapeutics Inc Business Profile
10.2 Cardero Therapeutics Inc Friedreich Ataxia Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Chondrial Therapeutics LLC Friedreich Ataxia Pipeline Details
11.1 Chondrial Therapeutics LLC Business Profile
11.2 Chondrial Therapeutics LLC Friedreich Ataxia Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 Horizon Pharma Plc Friedreich Ataxia Pipeline Details
12.1 Horizon Pharma Plc Business Profile
12.2 Horizon Pharma Plc Friedreich Ataxia Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Ixchel Pharma LLC Friedreich Ataxia Pipeline Details
13.1 Ixchel Pharma LLC Business Profile
13.2 Ixchel Pharma LLC Friedreich Ataxia Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 Jupiter Orphan Therapeutics Inc Friedreich Ataxia Pipeline Details
14.1 Jupiter Orphan Therapeutics Inc Business Profile
14.2 Jupiter Orphan Therapeutics Inc Friedreich Ataxia Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 Panorama Research Inc Friedreich Ataxia Pipeline Details
15.1 Panorama Research Inc Business Profile
15.2 Panorama Research Inc Friedreich Ataxia Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 PTC Therapeutics Inc Friedreich Ataxia Pipeline Details
16.1 PTC Therapeutics Inc Business Profile
16.2 PTC Therapeutics Inc Friedreich Ataxia Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 Reata Pharmaceuticals Inc Friedreich Ataxia Pipeline Details
17.1 Reata Pharmaceuticals Inc Business Profile
17.2 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 Retrotope Inc Friedreich Ataxia Pipeline Details
18.1 Retrotope Inc Business Profile
18.2 Retrotope Inc Friedreich Ataxia Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 STATegics Inc Friedreich Ataxia Pipeline Details
19.1 STATegics Inc Business Profile
19.2 STATegics Inc Friedreich Ataxia Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 Takeda Pharmaceutical Co Ltd Friedreich Ataxia Pipeline Details
20.1 Takeda Pharmaceutical Co Ltd Business Profile
20.2 Takeda Pharmaceutical Co Ltd Friedreich Ataxia Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21 Voyager Therapeutics Inc Friedreich Ataxia Pipeline Details
21.1 Voyager Therapeutics Inc Business Profile
21.2 Voyager Therapeutics Inc Friedreich Ataxia Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22. Latest Friedreich Ataxia Drug Pipeline Developments, 2019

23. Appendix
23.1 About Us
23.2 Sources and Methodology
23.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3
  • Adverum Biotechnologies Inc
  • Agios Pharmaceuticals Inc
  • Amylyx Pharmaceutical Corp
  • BioElectron Technology Corp
  • BioMarin Pharmaceutical Inc
  • Biovista Inc
  • Cardero Therapeutics Inc
  • Chondrial Therapeutics LLC
  • Horizon Pharma Plc
  • Ixchel Pharma LLC
  • Jupiter Orphan Therapeutics Inc
  • Panorama Research Inc
  • PTC Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • Retrotope Inc
  • STATegics Inc
  • Takeda Pharmaceutical Co Ltd
  • Voyager Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll